Applied Therapeutics, Inc. (APLT): Price and Financial Metrics
GET POWR RATINGS... FREE!
APLT Stock Price Chart Interactive Chart >
APLT Price/Volume Stats
| Current price | $17.32 | 52-week high | $29.80 |
| Prev. close | $15.68 | 52-week low | $13.04 |
| Day low | $15.64 | Volume | 128,000 |
| Day high | $17.79 | Avg. volume | 105,709 |
| 50-day MA | $16.54 | Dividend yield | N/A |
| 200-day MA | $19.54 | Market Cap | 453.40M |
Applied Therapeutics, Inc. (APLT) Company Bio
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY
Latest APLT News From Around the Web
Below are the latest news stories about Applied Therapeutics Inc that investors may wish to consider to help them evaluate APLT as an investment opportunity.
Is Applied Therapeutics (NASDAQ:APLT) Using Debt Sensibly?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the... |
Applied Therapeutics Stock Drops On Delayed NDA Submission For Its Lead CandidateApplied Therapeutics Inc (NASDAQ: APLT ) has reported initial biomarker data from the pediatric ACTION-Galactosemia |
Applied Therapeutics Reports Initial Pediatric Biomarker Data from ACTION-Galactosemia KidsSubstantial and statistically significant reduction in plasma galactitol Baseline analysis demonstrates clear relationship between plasma galactitol level and severity of disease in pediatric Galactosemia patients NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported initial biomar |
Applied Therapeutics Reports Second Quarter 2021 Financial ResultsNDA submission for AT-007 in Galactosemia expected in Q3 2021; commercial preparations ongoing Ended Q2 2021 with a strong balance sheet with $125.6 million in cash and cash equivalents and short-term investments NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial result |
Applied Therapeutics Added to Russell Microcap IndexNEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the Company has joined the Russell Microcap Index. The newly reconstituted index took effect after the market close on Friday, |
APLT Price Returns
| 1-mo | 12.03% |
| 3-mo | -16.65% |
| 6-mo | -4.89% |
| 1-year | -12.39% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -21.31% |
| 2020 | -19.32% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...